Which has preferable valuation & earnings, TLRY or NGEN?

NervGen Pharma has lower revenue, but higher earnings than Tilray Brands. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tilray Brands $821.31M 0.71 -$2.19B -$13.65 N/A NervGen Pharma N/A N/A N/A N/A N/A

Does the media refer more to TLRY or NGEN?

In the previous week, Tilray Brands had 19 more articles in the media than NervGen Pharma. MarketBeat recorded 23 mentions for Tilray Brands and 4 mentions for NervGen Pharma. Tilray Brands' average media sentiment score of 0.51 beat NervGen Pharma's score of 0.39 indicating that Tilray Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 3 Very Positive mention(s) 7 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, NGEN or PRME?

NervGen Pharma has higher earnings, but lower revenue than Prime Medicine. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NervGen Pharma N/A N/A N/A N/A N/A Prime Medicine $4.63M 108.45 -$201.14M -$1.23 N/A

Does the media prefer NGEN or PRME?

In the previous week, Prime Medicine had 3 more articles in the media than NervGen Pharma. MarketBeat recorded 7 mentions for Prime Medicine and 4 mentions for NervGen Pharma. Prime Medicine's average media sentiment score of 0.60 beat NervGen Pharma's score of 0.39 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend NGEN or ZSQR?

NervGen Pharma presently has a consensus target price of $18.00, suggesting a potential upside of 837.50%. Given NervGen Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe NervGen Pharma is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NervGen Pharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.80 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, NGEN or ZSQR?

NervGen Pharma has higher earnings, but lower revenue than Coeptis Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NervGen Pharma N/A N/A N/A N/A N/A Coeptis Therapeutics $1.36M 413.33 -$11.92M -$2.52 N/A

Does the media refer more to NGEN or ZSQR?

In the previous week, NervGen Pharma had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 4 mentions for NervGen Pharma and 3 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.62 beat NervGen Pharma's score of 0.39 indicating that Coeptis Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, NGEN or TECX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NervGen Pharma N/A N/A N/A N/A N/A Tectonic Therapeutic N/A N/A -$74.15M -$4.46 N/A

Is NGEN or TECX more profitable?

NervGen Pharma's return on equity of 0.00% beat Tectonic Therapeutic's return on equity. Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A N/A N/A Tectonic Therapeutic N/A -32.33% -30.92%

Does the media refer more to NGEN or TECX?

In the previous week, NervGen Pharma had 2 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 4 mentions for NervGen Pharma and 2 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.62 beat NervGen Pharma's score of 0.39 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, NGEN or PROK?

NervGen Pharma has higher earnings, but lower revenue than ProKidney. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NervGen Pharma N/A N/A N/A N/A N/A ProKidney $890K 556.60 -$68.99M -$0.53 N/A

Is NGEN or PROK more profitable?

NervGen Pharma has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%. Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A N/A N/A ProKidney -8,131.50% N/A -21.39%

NervGen Pharma (NGEN) Competitors

$1.92 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$1.94 +0.02 (+1.09%)

As of 06/12/2026 07:57 PM Eastern

Compare

NGEN vs. TLRY, PRME, ZSQR, TECX, and PROK

Should you buy NervGen Pharma stock or one of its competitors? MarketBeat compares NervGen Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NervGen Pharma include Tilray Brands (TLRY), Prime Medicine (PRME), Coeptis Therapeutics (ZSQR), Tectonic Therapeutic (TECX), and ProKidney (PROK). These companies are all part of the "pharmaceutical products" industry.

How does NervGen Pharma compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and NervGen Pharma (NASDAQ:NGEN) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

9.4% of Tilray Brands shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by insiders. Comparatively, 5.8% of NervGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Tilray Brands had 19 more articles in the media than NervGen Pharma. MarketBeat recorded 23 mentions for Tilray Brands and 4 mentions for NervGen Pharma. Tilray Brands' average media sentiment score of 0.51 beat NervGen Pharma's score of 0.39 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	3 Very Positive mention(s)	7 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NervGen Pharma has lower revenue, but higher earnings than Tilray Brands.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$821.31M	0.71	-$2.19B	-$13.65	N/A
NervGen Pharma	N/A	N/A	N/A	N/A	N/A

NervGen Pharma has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. NervGen Pharma's return on equity of 0.00% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-156.51%	-3.31%	-2.42%
NervGen Pharma	N/A	N/A	N/A

Tilray Brands currently has a consensus price target of $11.50, indicating a potential upside of 130.92%. NervGen Pharma has a consensus price target of $18.00, indicating a potential upside of 837.50%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts clearly believe NervGen Pharma is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.80

Summary

NervGen Pharma beats Tilray Brands on 7 of the 12 factors compared between the two stocks.

How does NervGen Pharma compare to Prime Medicine?

NervGen Pharma (NASDAQ:NGEN) and Prime Medicine (NASDAQ:PRME) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

70.4% of Prime Medicine shares are held by institutional investors. 5.8% of NervGen Pharma shares are held by insiders. Comparatively, 16.0% of Prime Medicine shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

NervGen Pharma currently has a consensus price target of $18.00, suggesting a potential upside of 837.50%. Prime Medicine has a consensus price target of $7.65, suggesting a potential upside of 175.18%. Given NervGen Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe NervGen Pharma is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.80
Prime Medicine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

NervGen Pharma has higher earnings, but lower revenue than Prime Medicine.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	N/A	N/A	N/A
Prime Medicine	$4.63M	108.45	-$201.14M	-$1.23	N/A

In the previous week, Prime Medicine had 3 more articles in the media than NervGen Pharma. MarketBeat recorded 7 mentions for Prime Medicine and 4 mentions for NervGen Pharma. Prime Medicine's average media sentiment score of 0.60 beat NervGen Pharma's score of 0.39 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NervGen Pharma has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. NervGen Pharma's return on equity of 0.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	N/A	N/A
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Summary

NervGen Pharma and Prime Medicine tied by winning 6 of the 12 factors compared between the two stocks.

How does NervGen Pharma compare to Coeptis Therapeutics?

NervGen Pharma (NASDAQ:NGEN) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

NervGen Pharma has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. NervGen Pharma's return on equity of 0.00% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	N/A	N/A
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

NervGen Pharma has higher earnings, but lower revenue than Coeptis Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	N/A	N/A	N/A
Coeptis Therapeutics	$1.36M	413.33	-$11.92M	-$2.52	N/A

In the previous week, NervGen Pharma had 1 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 4 mentions for NervGen Pharma and 3 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.62 beat NervGen Pharma's score of 0.39 indicating that Coeptis Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

13.9% of Coeptis Therapeutics shares are held by institutional investors. 5.8% of NervGen Pharma shares are held by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

NervGen Pharma presently has a consensus target price of $18.00, suggesting a potential upside of 837.50%. Given NervGen Pharma's stronger consensus rating and higher possible upside, equities research analysts plainly believe NervGen Pharma is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.80
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

NervGen Pharma beats Coeptis Therapeutics on 8 of the 12 factors compared between the two stocks.

How does NervGen Pharma compare to Tectonic Therapeutic?

NervGen Pharma (NASDAQ:NGEN) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

NervGen Pharma currently has a consensus price target of $18.00, suggesting a potential upside of 837.50%. Tectonic Therapeutic has a consensus price target of $79.40, suggesting a potential upside of 162.22%. Given NervGen Pharma's higher possible upside, equities research analysts clearly believe NervGen Pharma is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.80
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	N/A	N/A	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

NervGen Pharma's return on equity of 0.00% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	N/A	N/A
Tectonic Therapeutic	N/A	-32.33%	-30.92%

62.6% of Tectonic Therapeutic shares are held by institutional investors. 5.8% of NervGen Pharma shares are held by insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, NervGen Pharma had 2 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 4 mentions for NervGen Pharma and 2 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.62 beat NervGen Pharma's score of 0.39 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tectonic Therapeutic beats NervGen Pharma on 5 of the 9 factors compared between the two stocks.

How does NervGen Pharma compare to ProKidney?

NervGen Pharma (NASDAQ:NGEN) and ProKidney (NASDAQ:PROK) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

51.6% of ProKidney shares are owned by institutional investors. 5.8% of NervGen Pharma shares are owned by insiders. Comparatively, 39.8% of ProKidney shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

NervGen Pharma currently has a consensus target price of $18.00, indicating a potential upside of 837.50%. ProKidney has a consensus target price of $7.40, indicating a potential upside of 351.22%. Given NervGen Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe NervGen Pharma is more favorable than ProKidney.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.80
ProKidney	2 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

NervGen Pharma has a net margin of 0.00% compared to ProKidney's net margin of -8,131.50%.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	N/A	N/A
ProKidney	-8,131.50%	N/A	-21.39%

NervGen Pharma has higher earnings, but lower revenue than ProKidney.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	N/A	N/A	N/A
ProKidney	$890K	556.60	-$68.99M	-$0.53	N/A

In the previous week, NervGen Pharma had 3 more articles in the media than ProKidney. MarketBeat recorded 4 mentions for NervGen Pharma and 1 mentions for ProKidney. ProKidney's average media sentiment score of 1.87 beat NervGen Pharma's score of 0.39 indicating that ProKidney is being referred to more favorably in the news media.

Company	Overall Sentiment
NervGen Pharma	Neutral
ProKidney	Very Positive

Summary

NervGen Pharma beats ProKidney on 6 of the 11 factors compared between the two stocks.

Get NervGen Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NGEN vs. The Competition

Export

Metric	NervGen Pharma	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$154.81M	$2.95B	$4.29B	$12.05B
Dividend Yield	N/A	15.26%	10.25%	5.66%
P/E Ratio	N/A	13.63	22.29	24.42
Price / Sales	N/A	3,048.38	159.54	118.72
Price / Cash	N/A	26.81	40.19	37.92
Price / Book	N/A	4.80	26.92	6.82
Net Income	N/A	-$39.47M	$116.61M	$337.56M
7 Day Performance	5.49%	0.47%	0.25%	1.16%
1 Month Performance	-46.22%	0.64%	0.25%	3.16%
1 Year Performance	N/A	16.43%	14.25%	30.60%

NervGen Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NGEN NervGen Pharma	4.3192 of 5 stars	$1.92 flat	$18.00 +837.5%	N/A	$154.81M	N/A	N/A	N/A	Short Interest Increase
TLRY Tilray Brands	3.5848 of 5 stars	$4.95 +0.2%	$11.50 +132.3%	+23.3%	$582.05M	$210.48M	N/A	2,842	Gap Up
PRME Prime Medicine	2.0769 of 5 stars	$3.11 +1.6%	$7.65 +146.0%	N/A	$564.98M	$4.63M	N/A	N/A	News Coverage Gap Up
ZSQR Coeptis Therapeutics	0.301 of 5 stars	$10.98 +8.5%	N/A	+30.7%	$564.70M	$1.36M	N/A	2	Analyst Downgrade Gap Down
TECX Tectonic Therapeutic	3.0994 of 5 stars	$29.26 +0.9%	$79.40 +171.4%	+38.3%	$553.12M	N/A	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NGEN) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NervGen Pharma (NGEN) Competitors

NGEN vs. TLRY, PRME, ZSQR, TECX, and PROK

How does NervGen Pharma compare to Tilray Brands?

Summary

How does NervGen Pharma compare to Prime Medicine?

Summary

How does NervGen Pharma compare to Coeptis Therapeutics?

Summary

How does NervGen Pharma compare to Tectonic Therapeutic?

Summary

How does NervGen Pharma compare to ProKidney?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN vs. The Competition

NervGen Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NervGen Pharma (NGEN) Competitors

NGEN vs. TLRY, PRME, ZSQR, TECX, and PROK

How does NervGen Pharma compare to Tilray Brands?

Do insiders and institutionals have more ownership in TLRY or NGEN?

Does the media refer more to TLRY or NGEN?

Which has preferable valuation & earnings, TLRY or NGEN?

Is TLRY or NGEN more profitable?

Do analysts recommend TLRY or NGEN?

Summary

How does NervGen Pharma compare to Prime Medicine?

Do insiders & institutionals believe in NGEN or PRME?

Do analysts recommend NGEN or PRME?

Which has better earnings & valuation, NGEN or PRME?

Does the media prefer NGEN or PRME?

Is NGEN or PRME more profitable?

Summary

How does NervGen Pharma compare to Coeptis Therapeutics?

Is NGEN or ZSQR more profitable?

Which has higher earnings and valuation, NGEN or ZSQR?

Does the media refer more to NGEN or ZSQR?

Do insiders and institutionals believe in NGEN or ZSQR?

Do analysts recommend NGEN or ZSQR?

Summary

How does NervGen Pharma compare to Tectonic Therapeutic?

Do analysts rate NGEN or TECX?

Which has higher earnings & valuation, NGEN or TECX?

Is NGEN or TECX more profitable?

Do insiders & institutionals believe in NGEN or TECX?

Does the media refer more to NGEN or TECX?

Summary

How does NervGen Pharma compare to ProKidney?

Do insiders & institutionals have more ownership in NGEN or PROK?

Do analysts rate NGEN or PROK?

Is NGEN or PROK more profitable?

Which has preferable valuation and earnings, NGEN or PROK?

Does the media prefer NGEN or PROK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN vs. The Competition

NervGen Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools